- Home
- ABVC vs ACRV Comparison
ABVC vs ACRV Comparison
Compare ABVC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ACRV
- Stock Information
- Founded
- ABVC 2015
- ACRV 2018
- Country
- ABVC United States
- ACRV United States
- Employees
- ABVC N/A
- ACRV N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ABVC Health Care
- ACRV Health Care
- Exchange
- ABVC Nasdaq
- ACRV Nasdaq
- Market Cap
- ABVC 52.1M
- ACRV 47.8M
- IPO Year
- ABVC N/A
- ACRV 2022
- Fundamental
- Price
- ABVC $2.72
- ACRV $1.67
- Analyst Decision
- ABVC
- ACRV Buy
- Analyst Count
- ABVC 0
- ACRV 6
- Target Price
- ABVC N/A
- ACRV $17.75
- AVG Volume (30 Days)
- ABVC 82.8K
- ACRV 3.5M
- Earning Date
- ABVC 11-13-2025
- ACRV 11-12-2025
- Dividend Yield
- ABVC N/A
- ACRV N/A
- EPS Growth
- ABVC N/A
- ACRV N/A
- EPS
- ABVC N/A
- ACRV N/A
- Revenue
- ABVC $391,242.00
- ACRV N/A
- Revenue This Year
- ABVC $735.18
- ACRV N/A
- Revenue Next Year
- ABVC N/A
- ACRV $805.34
- P/E Ratio
- ABVC N/A
- ACRV N/A
- Revenue Growth
- ABVC 186.84
- ACRV N/A
- 52 Week Low
- ABVC $0.40
- ACRV $1.05
- 52 Week High
- ABVC $5.48
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- ABVC 45.18
- ACRV 64.34
- Support Level
- ABVC $2.64
- ACRV $1.46
- Resistance Level
- ABVC $2.90
- ACRV $2.67
- Average True Range (ATR)
- ABVC 0.16
- ACRV 0.20
- MACD
- ABVC 0.00
- ACRV 0.01
- Stochastic Oscillator
- ABVC 33.87
- ACRV 27.01
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.